How big is the biosimulation market?

The global biosimulation market size was valued at USD 4.1 billion in 2025 and is estimated at USD 4.8 billion for 2026.

What is the biosimulation market growth rate?

The global biosimulation market is expected to grow at a CAGR of 17.3% from 2026 to 2033, reaching USD 14.8 billion.

What are the factors driving the biosimulation market?

Key factors include growing regulatory support for model-informed drug development (MIDD), AI/ML integration in computational modeling, rising R&D costs, and increasing demand for personalized medicine.

Which region dominated the biosimulation market?

North America dominated with a 44.2% revenue share in 2025.

Which is the fastest-growing regional market?

Asia Pacific is the fastest-growing region over the forecast period.

Which product segment leads the biosimulation market?

The software segment led with a 59.4% revenue share in 2025, while services is the fastest-growing segment.

Which therapeutic area dominated the biosimulation market?

Oncology held the largest revenue share in 2025, while infectious diseases is the fastest-growing area.

Which deployment model leads the biosimulation market?

Cloud-based deployment held the largest share (over 43.0%) in 2025 and is the fastest-growing model.

Who are the key players in the biosimulation market?

Key players include Certara, Dassault Systèmes, Simulations Plus, Schrödinger, Chemical Computing Group, Physiomics Plc, Rosa & Co. LLC, BioSimulation Consulting Inc., Genedata AG, Instem, Thermo Fisher Scientific, Advanced Chemistry Development (part of Revvity), and Yokogawa.